# Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

> **NCT07299292** · PHASE2 · RECRUITING · sponsor: **SMED Clinical Research** · enrollment: 60 (estimated)

## Conditions studied

- Prostate Cancer (Diagnosis)

## Interventions

- **DRUG:** Abiraterone 250 mg with food + prednisone

## Key facts

- **NCT ID:** NCT07299292
- **Lead sponsor:** SMED Clinical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-03-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07299292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07299292, "Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07299292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*